StreetInsider.com News Articles

Ligand to Participate in September Investor Conferences

Wed, 26 Aug 2026 07:00:00 -0400

JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences:

Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.
Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.
H.C. Wainwright 28th Annual Global Investment Conference (New York): Management will present on September 14, 2026 at 10:00 a.m. ET.

Ligand

Ligand to Participate in September Investor Conferences

Wed, 26 Aug 2026 07:00:00 -0400

Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.
Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.
H.C. Wainwright 28th Annual Global Investment Conference (New York): Management will present on September 14, 2026 at 10:00 a.m. ET.

Ligand

Ligand to Participate in September Investor Conferences

Wed, 26 Aug 2026 07:00:00 -0400

Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.
Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.
H.C. Wainwright 28th Annual Global Investment Conference (New York): Management will present on September 14, 2026 at 10:00 a.m. ET.

Ligand

Ligand to Participate in September Investor Conferences

Wed, 26 Aug 2026 07:00:00 -0400

Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.
Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.
H.C. Wainwright 28th Annual Global Investment Conference (New York): Management will present on September 14, 2026 at 10:00 a.m. ET.

Ligand

Form 4 LIGAND PHARMACEUTICALS For: Aug 12 Filed by: Espinoza Octavio

Fri, 14 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26932597.html

Form 4 LIGAND PHARMACEUTICALS For: Aug 12 Filed by: Espinoza Octavio

Fri, 14 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26932597.html

Form 4 LIGAND PHARMACEUTICALS For: Aug 12 Filed by: Haas Jason

Fri, 14 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26932545.html

Form 4 LIGAND PHARMACEUTICALS For: Aug 12 Filed by: Haas Jason

Fri, 14 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26932545.html

Leerink Starts Ligand Pharma (LGND) at Outperform

Fri, 14 Aug 2026 09:29:51 -0400

Leerink analyst David Risinger initiates coverage on Ligand Pharma (NASDAQ: LGND) with a Outperform rating and a price target of $330.00.

For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.

Shares of Ligand Pharma closed at $288.82 yesterday.

Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO

Fri, 14 Aug 2026 08:21:07 -0400

Stifel analyst Annabel Samimy reiterated a Buy rating and $332.00 price target on Ligand Pharma (NASDAQ: LGND).

The analyst commented, "At our Biotech Summer Summit, we sat with CEO Todd Davis, CFO Tavo Espinoza, and VP of Portfolio Strategy and Investment Lauren Hay to discuss LGND’s differentiated and strengthening position within the biopharma royalty aggregation space, particularly now after its value-accretive acquisition of XOMA has added 120+ new assets to the portfolio and +50% annual cash flow generation. Despite the access to additional deployable capital, LGND’s primary investment strategy remains unchanged, targeting multiple sub-$100mn individual deals each year to sustain >20%

Form SCHEDULE 13G LIGAND PHARMACEUTICALS Filed by: Invesco Ltd.

Thu, 13 Aug 2026 14:59:00 -0400

si-local-file:///var/storage/secattach/20260813/26920079.html

Form SCHEDULE 13G LIGAND PHARMACEUTICALS Filed by: Invesco Ltd.

Thu, 13 Aug 2026 14:59:00 -0400

si-local-file:///var/storage/secattach/20260813/26920079.html

Form 144 LIGAND PHARMACEUTICALS Filed by: Espinoza Octavio

Wed, 12 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260812/26913547.html

Form 144 LIGAND PHARMACEUTICALS Filed by: Espinoza Octavio

Wed, 12 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260812/26913547.html

Form 144 LIGAND PHARMACEUTICALS Filed by: Haas Jason

Wed, 12 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260812/26913307.html

Form 144 LIGAND PHARMACEUTICALS Filed by: Haas Jason

Wed, 12 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260812/26913307.html

Form 10-Q LIGAND PHARMACEUTICALS For: Jun 30

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891028.html

Form 10-Q LIGAND PHARMACEUTICALS For: Jun 30

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891028.html

Ligand Pharma (LGND) PT Raised to $345 at RBC Capital

Fri, 07 Aug 2026 07:21:37 -0400

RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $345.00 (from $340.00) while maintaining a Outperform rating.

Ligand Pharma (LGND) Tops Q2 EPS by 42c

Thu, 06 Aug 2026 07:17:27 -0400

Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $2.37, $0.42 better than the analyst estimate of $1.95. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $62.93 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

Form 8-K LIGAND PHARMACEUTICALS For: Aug 06

Thu, 06 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26878500.html

Form 8-K LIGAND PHARMACEUTICALS For: Aug 06

Thu, 06 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26878500.html

Ligand Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Second quarter performance driven by strong year-over-year royalty revenue growth of 32%

Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged

Conference call begins at 8:30 a.m. Eastern Time today

JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions.

Ligand Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Second quarter performance driven by strong year-over-year royalty revenue growth of 32%

Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged

Conference call begins at 8:30 a.m. Eastern Time today

Ligand Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Second quarter performance driven by strong year-over-year royalty revenue growth of 32%

Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged

Conference call begins at 8:30 a.m. Eastern Time today